We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
An SI Board Since January 2003
Posts SubjectMarks Bans
21 1 0
Emcee:  afrayem onigwecher Type:  Moderated
FDA Clears BioCurex Histo-RECAF Kit for Commercialization as a Class I Device
Wednesday January 22, 11:34 am ET

RANCHO SANTA MARGARITA, Calif., Jan. 22, 2003 (PRIMEZONE) -- BioCurex Inc. (OTC BB:BOCX.OB - News) announces that its first product, Histo-RECAF(TM) has been classified by the FDA as a Class I device under Regulation Number 864.1850, Code HZJ owned by BioCurex (FDA number 9046509). Thus, the product is now available as a ``Staining test for AFP receptors (a.k.a. RECAF) in tissues'' for sale to pathology laboratories across the USA (FDA text available at )
Dr. Ricardo Moro, President of BioCurex commented: ``We are very excited by this ruling since it will allow us to start commercializing Histo-RECAF(TM) in thousands of laboratories in the USA. Also, the FDA ruling and the previously announced notice of allowance by the U.S. Patent office are the two elements required for licensing this technology to other biopharmaceutical companies.''

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging ad therapeutics. The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. The Histo-RECAF(TM) kits provide proof of concept for the RECAF technology. Detailed information about BioCurex may be obtained from their Website at


The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are ``forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.

BioCurex, Inc.
Ricardo Moro
(866) 884-8669

Source: BioCurex, Inc.
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
21<i>the company will increase its authorized capital from 150 million to 45scion-3/12/2003
20BioCurex Announces a Proposed 3 for 1 Forward Split onigwecher-3/12/2003
19Search term: RECAF Word Mark RECAF Goods and Services (CANCELLED) IC 030. US 0scion-3/11/2003
17RECAF(TM ) Word Mark RECAF Goods and Services (CANCELLED) IC 030. US 046. G &ascion-3/11/2003
16Huge market potential - no product to sell to it - is that correct? <i>A scion-3/11/2003
15NEWS ALERT Biocurex, Inc. (OTCBB: BOCX) 6 Month Target Price: $1.26 Shares afrayem onigwecher-3/11/2003
14Two different names for the same person - that could be confusing. Dr. Ricardoscion-3/10/2003
13United States Patent 6,514,685 Moro February 4, 2003 -------------------------scion-3/10/2003
12WHISPERING OAKS INTERNATIONAL INC filed this 10KSB/A on 02/18/2003. BOCX ITEscion-3/10/2003
11Insider & Form 144 Roster - BIOCUREX INC (OTC BB:BOCX.OB) Insider & rescion-3/10/2003
10RJV Network News Release Tuesday, 03-Dec-2002 10:20AM PST BELLEVUE, Wash.--(Bscion-3/10/2003
9BioCurex and RJV Networks Create a Non-Toxic Therapeutic Antibody Cancer Treatmescion-3/10/2003
8BOCX: See my earlier DD. It appears that the licensing came from RJVN, a compainchingup-3/10/2003
7NEWS ALERT Biocurex, Inc. (OTCBB: BOCX) 6 Month Target Price: $1.26 Shares afrayem onigwecher-3/10/2003
6---BioCurex Granted U.S. Patent For Cancer Diagnostic Products and FDA Clearanceinchingup-3/10/2003
5CEOcast Features BioCurex's Chairman onigwecher-3/10/2003
4BioCurex Granted U.S. Patent For Cancer Diagnostic Products and FDA Clearance wiafrayem onigwecher-3/10/2003
3afrayem: Spent almost the entire week-end researching BOCX and RJVN. The deainchingup-2/3/2003
2afrayem: you should include this too. Press Release Source: BioCurex, Inc. Biinchingup-1/26/2003
1BioCurex in Discussions with Several Investment Groups onigwecher-1/23/2003
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):